Newly Designed Poxviral Promoters to Improve Immunogenicity and Efficacy of MVA-NP Candidate Vaccines against Lethal Influenza Virus Infection in Mice
Authors:
- Martin C. LangenmayerMLMartin C. Langenmayer
- Anna-Theresa Luelf-AverhoffALAnna-Theresa Luelf-Averhoff
- Lisa MarrLMLisa Marr
- Sylvia JanySJSylvia Jany
- Astrid FreudensteinAFAstrid Freudenstein
- Silvia Adam-NeumairSASilvia Adam-Neumair
- Alina TscherneATAlina Tscherne
- Robert FuxRFRobert Fux
- Juan J. RojasJRJuan J. Rojas
- Andreas BlutkeABAndreas Blutke
- Gerd SutterGSGerd Sutter
- Asisa VolzAVAsisa Volz
Open Access
Abstract
Influenza, a respiratory disease mainly caused by influenza A and B, viruses of the Orthomyxoviridae, is still a burden on our society’s health and economic system. Influenza A viruses (IAV) circulate in mammalian and avian populations, causing seasonal outbreaks with high numbers of cases. Due to the high variability in seasonal IAV triggered by antigenic drift, annual vaccination is necessary, highlighting the need for a more broadly protective vaccine against IAV. The safety tested Modified Vaccinia virus Ankara (MVA) is licensed as a third-generation vaccine against smallpox and serves as a potent vector system for the development of new candidate vaccines against different pathogens. Here, we generated and characterized recombinant MVA candidate vaccines that deliver the highly conserved internal nucleoprotein (NP) of IAV under the transcriptional control of five newly designed chimeric poxviral promoters to further increase the immunogenic properties of the recombinant viruses (MVA-NP). Infections of avian cell cultures with the recombinant MVA-NPs demonstrated efficient synthesis of the IAV-NP which was expressed under the control of the five new promoters. Prime-boost or single shot immunizations in C57BL/6 mice readily induced circulating serum antibodies’ binding to recombinant IAV-NP and the robust activation of IAV-NP-specific CD8+ T cell responses. Moreover, the MVA-NP candidate vaccines protected C57BL/6 mice against lethal respiratory infection with mouse-adapted IAV (A/Puerto Rico/8/1934/H1N1). Thus, further studies are warranted to evaluate the immunogenicity and efficacy of these recombinant MVA-NP vaccines in other IAV challenge models in more detail.Keywords
Funding Information
- European Commission (602604, 874650, TTU01.901, TTU01.802)
- European Commission (602604, 874650, TTU01.901, TTU01.802)
- German Centre for Infection Research (602604, 874650, TTU01.901, TTU01.802)
This publication has 70 references indexed in Scilit:
- Expression and Cellular Immunogenicity of a Transgenic Antigen Driven by Endogenous Poxviral Early Promoters at Their Authentic Loci in MVAPLOS ONE, 2012
- Preliminary Assessment of the Efficacy of a T-Cell–Based Influenza Vaccine, MVA-NP+M1, in HumansClinical Infectious Diseases, 2012
- Discordant antigenic drift of neuraminidase and hemagglutinin in H1N1 and H3N2 influenza virusesProceedings of the National Academy of Sciences, 2011
- Regulation of Antinucleoprotein IgG by Systemic Vaccination and Its Effect on Influenza Virus ClearanceJournal of Virology, 2011
- Potent CD8+ T-Cell Immunogenicity in Humans of a Novel Heterosubtypic Influenza A Vaccine, MVA-NP+M1Clinical Infectious Diseases, 2011
- Immediate-Early Expression of a Recombinant Antigen by Modified Vaccinia Virus Ankara Breaks the Immunodominance of Strong Vector-Specific B8R Antigen in Acute and Memory CD8 T-Cell ResponsesJournal of Virology, 2010
- Modified H5 promoter improves stability of insert genes while maintaining immunogenicity during extended passage of genetically engineered MVA vaccinesVaccine, 2010
- Cross-Priming of Cytotoxic T Cells Dictates Antigen Requisites for Modified Vaccinia Virus Ankara Vector VaccinesJournal of Virology, 2007
- Cross-competition of CD8+ T cells shapes the immunodominance hierarchy during boost vaccinationJournal of Experimental Medicine, 2007
- Mapping the Antigenic and Genetic Evolution of Influenza VirusScience, 2004